Medy-Tox Inc. (KOSDAQ:086900)

Medy-Tox Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	234,632	228,622	221,121	195,096	184,870	140,828
Other Revenue	-	-	-	-0	-0	-
Revenue	234,632	228,622	221,121	195,096	184,870	140,828
Revenue Growth (YoY)	-4.72%	3.39%	13.34%	5.53%	31.27%	-31.60%
Cost of Revenue	99,835	90,038	87,625	69,048	79,397	66,928
Gross Profit	134,798	138,584	133,496	126,048	105,473	73,900
Selling, General & Admin	76,192	78,370	86,605	47,679	41,938	59,544
Research & Development	29,821	29,821	25,133	23,324	23,267	32,544
Amortization of Goodwill & Intangibles	2,282	2,282	1,284	799.22	834.58	662.42
Other Operating Expenses	1,346	1,346	1,322	1,242	1,216	1,403
Operating Expenses	116,057	118,236	116,173	79,383	72,335	110,969
Operating Income	18,740	20,349	17,322	46,665	33,138	-37,070
Interest Expense	-1,727	-1,727	-2,333	-2,314	-4,781	-4,176
Interest & Investment Income	925.15	925.15	896.43	610.76	957.22	340.02
Earnings From Equity Investments	6,765	5,877	1,363	5,129	-1,456	-2,432
Currency Exchange Gain (Loss)	4,387	4,387	475.22	3,425	2,111	-376.81
Other Non Operating Income (Expenses)	-3,440	-4,138	-605.87	-715.84	108,431	6,967
EBT Excluding Unusual Items	25,651	25,673	17,118	52,800	138,400	-36,748
Impairment of Goodwill	-	-	-	-	-	-711.12
Gain (Loss) on Sale of Investments	126.49	126.49	-593.36	-3,044	2,666	-1,067
Gain (Loss) on Sale of Assets	323.58	323.58	-671.97	-230.42	131.48	58.63
Asset Writedown	-8,624	-8,624	-	-	-12,932	-3,671
Pretax Income	17,477	17,499	15,853	49,526	128,265	-42,139
Income Tax Expense	-247.33	1,425	6,163	12,930	35,003	-12,100
Earnings From Continuing Operations	17,724	16,074	9,690	36,596	93,263	-30,039
Minority Interest in Earnings	1,469	881.22	65.28	414.16	891.27	462.11
Net Income	19,193	16,955	9,755	37,010	94,154	-29,577
Preferred Dividends & Other Adjustments	975	975	975	975.33	974.73	0.7
Net Income to Common	18,218	15,980	8,780	36,035	93,179	-29,577
Net Income Growth	244.57%	73.81%	-73.64%	-60.69%	-	-
Shares Outstanding (Basic)	6	7	7	7	6	6
Shares Outstanding (Diluted)	6	7	7	7	6	6
Shares Change (YoY)	-2.69%	0.40%	2.02%	2.28%	0.04%	-0.82%
EPS (Basic)	2832.89	2376.57	1311.06	5491.68	14587.59	-4609.95
EPS (Diluted)	2832.89	2376.57	1311.00	5489.34	14517.37	-4610.30
EPS Growth	307.46%	81.28%	-76.12%	-62.19%	-	-
Free Cash Flow	46,244	27,830	5,862	16,304	2,452	-13,217
Free Cash Flow Per Share	7191.04	4138.95	875.31	2483.66	382.01	-2059.99
Dividend Per Share	1100.000	1100.000	-	-	-	-
Gross Margin	57.45%	60.62%	60.37%	64.61%	57.05%	52.48%
Operating Margin	7.99%	8.90%	7.83%	23.92%	17.93%	-26.32%
Profit Margin	7.76%	6.99%	3.97%	18.47%	50.40%	-21.00%
Free Cash Flow Margin	19.71%	12.17%	2.65%	8.36%	1.33%	-9.38%
EBITDA	38,852	40,307	32,698	61,766	51,394	-18,472
EBITDA Margin	16.56%	17.63%	14.79%	31.66%	27.80%	-13.12%
D&A For EBITDA	20,112	19,959	15,376	15,101	18,256	18,597
EBIT	18,740	20,349	17,322	46,665	33,138	-37,070
EBIT Margin	7.99%	8.90%	7.83%	23.92%	17.93%	-26.32%
Effective Tax Rate	-	8.15%	38.88%	26.11%	27.29%	-
Advertising Expenses	-	7,146	5,976	3,351	2,031	3,839

Source: S&P Global Market Intelligence. Standard template. Financial Sources.